Drugs / COR-1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01391507 | Oct 2011 → Aug 2013 | dilated cardiomyopathy | Corimmun GmbH | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01043146 Comparator | Oct 2009 → Jan 2010 | heart failure | Corimmun GmbH | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | COR-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01391507 ↗ |
| Action | Inhibit | “COR-1 cyclopeptide has been shown to bind to, and therefore decrease, the anti-beta1-receptor autoantibody titre” NCT01391507 ↗ |
| Modality | Peptide | “the cyclic peptide COR-1 (given i.v. once monthly)” PMID 22968742 ↗ Sep 2012 |
| Route | Intravenous | “Monthly intravenous injection for 6 months” NCT01391507 ↗ |